THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
100.43%
Total 13F principal
$214,052,583
Principal change
-$13,360,917
Total reported market value
$215,080,235
Number of holders
25
Value change
-$13,282,274
Number of buys
11
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q1 2021

As of 31 Mar 2021, THERAVANCE INC - CORPORATE OBLIG was held by 25 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $214,052,583 in principal (par value) of the bond. The largest 10 bondholders included LAZARD ASSET MANAGEMENT LLC, Linden Advisors LP, ADVENT CAPITAL MANAGEMENT /DE/, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., OAKTREE CAPITAL MANAGEMENT LP, Shaolin Capital Management LLC, CNH PARTNERS LLC, DEUTSCHE BANK AG\, and Radcliffe Capital Management, L.P.. This page lists 25 institutional bondholders reporting positions for the Q1 2021 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.